EU-Japan Biotech & Pharma Partnering Conference 2026

16 Sept – 5 Oct 2026 | Osaka, Japan

HomeAgenda
Register
Register
Register

InvestmentUpdated on 28 September 2026

NaDeNo Series A | Drug delivery platform and PACAB-002 for ovarian cancer

About

NaDeNo is raising a €15m Series A to advance PACAB-002, our lead platform-enabled candidate for eradicating peritoneal micrometastases in ovarian cancer, through clinical development and to expand our drug delivery platform with several pipeline projects.

NaDeNo has a differentiated and versatile drug delivery platform and a clear first clinical application with strong momentum.

Major points of traction:

  1. PACAB-002 is on track to start Phase 1 in early 2027.

  2. NaDeNo has received €10m in blended finance from the EIC Accelerator program.

  3. Our platform is expanding through active collaborations, including work on oral delivery with AstraZeneca.